GSK (GSK) Stock Forecast & Price Target

$35.92 +0.55 (+1.54%)

Closing price 03:59 PM Eastern

Extended Trading

$35.74 -0.18 (-0.50%)

As of 06:10 PM Eastern

GSK - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
8

Buy
3

Based on 11 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 8 have given a hold rating, and 3 have given a strong buy rating for GSK.

Consensus Price Target

$40.58
13.00% Upside

According to the 11 analysts' twelve-month price targets for GSK, the average price target is $40.58. The highest price target for GSK is $47.00, while the lowest price target for GSK is $35.25. The average price target represents a forecasted upside of 13.00% from the current price of $35.92.

Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

GSK Analyst Ratings Over Time

Type	Current Forecast 4/17/24 to 4/17/25	1 Month Ago 3/18/24 to 3/18/25	3 Months Ago 1/18/24 to 1/17/25	1 Year Ago 4/18/23 to 4/17/24
Strong Buy	3 Strong Buy rating(s)	3 Strong Buy rating(s)	3 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	0 Buy rating(s)	3 Buy rating(s)
Hold	8 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$40.58	$43.25	$43.25	N/A
Forecasted Upside	13.00% Upside	7.20% Upside	29.28% Upside	N/A
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

Remove Ads

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GSK Stock vs. The Competition

Type	GSK	Medical Companies	S&P 500
Consensus Rating Score	2.55	2.81	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	13.00% Upside	21,674.57% Upside	26.48% Upside
News Sentiment Rating	Positive News See Recent GSK News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/15/2025	BNP Paribas 3 of 5 stars	Peter Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$35.25	-1.07%
2/12/2025	Morgan Stanley 3 of 5 stars		Initiated Coverage	Equal Weight
11/15/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Downgrade	Buy ➝ Hold
11/12/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$53.00 ➝ $39.50	+8.64%
10/31/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Fernandez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/27/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Field Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/7/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/8/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hauber Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
6/24/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/20/2024	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Holford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$47.00	+6.12%
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Reduce

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:27 PM ET.

Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 15, 2025. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

Here are some ways that investors could benefit from investing in GSK plc:

GSK plc recently reported earnings per share (EPS) of $0.59, exceeding analysts' expectations of $0.44, indicating strong financial performance and potential for future growth.
The stock price of GSK plc is currently $35.63, reflecting a 1.0% increase, which may suggest positive market sentiment and investor confidence.
Institutional investors hold 15.74% of GSK plc's stock, indicating a level of trust and interest from large financial entities, which can be a positive signal for retail investors.
GSK plc has a solid market capitalization of approximately $73.51 billion, which provides stability and resources for ongoing research and development in the pharmaceutical sector.
Recent upgrades from analysts, including a "strong-buy" rating, suggest that market experts see potential for significant appreciation in GSK plc's stock value.

GSK
Bear Case

Investors should be bearish about investing in GSK plc for these reasons:

GSK plc's stock has experienced volatility, with a 52-week low of $31.72, which may raise concerns about its stability and long-term performance.
Recent reports indicate that Arrowstreet Capital Limited Partnership significantly reduced its holdings in GSK plc by 94.4%, which could signal a lack of confidence from major investors.
The company's debt-to-equity ratio stands at 1.12, suggesting that GSK plc has a relatively high level of debt compared to its equity, which could pose risks in times of economic downturns.
Despite recent positive earnings, GSK plc's net margin of 8.13% may be considered low compared to industry standards, indicating potential challenges in profitability.
Market analysts have mixed ratings, with some maintaining a "hold" rating, which may indicate uncertainty about the stock's future performance.

GSK Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is $40.58, with a high forecast of $47.00 and a low forecast of $35.25.
: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last year. There are currently 8 hold ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GSK shares.
: According to analysts, GSK's stock has a predicted upside of 13.00% based on their 12-month stock forecasts.
: GSK has been rated by research analysts at BNP Paribas, and Morgan Stanley in the past 90 days.
: Analysts like GSK less than other "medical" companies. The consensus rating score for GSK is 2.55 while the average consensus rating score for "medical" companies is 2.81. Learn more on how GSK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:GSK) was last updated on 4/17/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Stock Forecast & Price Target